Anzeige
Mehr »
Login
Mittwoch, 19.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Doppeltes “STRONG BUY”! Jetzt bei EAM einsteigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEXG | ISIN: US81663L2007 | Ticker-Symbol:
NASDAQ
18.06.24
22:00 Uhr
27,600 US-Dollar
-0,140
-0,50 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
GENEDX HOLDINGS CORP Chart 1 Jahr
5-Tage-Chart
GENEDX HOLDINGS CORP 5-Tage-Chart

Aktuelle News zur GENEDX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.06.GeneDx Holdings Corp.: GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients128-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating...
► Artikel lesen
05.06.GeneDx Holdings Corp.: GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients79STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access...
► Artikel lesen
22.05.GeneDx Holdings Corp.: GeneDx to Participate in Upcoming Investor Conferences2
16.05.Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More7
30.04.Pre-market Movers: Cyclacel Pharmaceuticals, Marin Software, GeneDx, Sensata Technologies, Lichen China979INDIANAPOLIS (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.05 A.M. ET).In the Green Cyclacel Pharmaceuticals, Inc. (CYCC) is up...
► Artikel lesen
30.04.Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket4
30.04.Earnings call: GeneDx reports 51% revenue surge, eyes profitability by 2025-
29.04.GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance2
29.04.GeneDx reports Q1 results1
29.04.GeneDx Holdings Corp. - 10-Q, Quarterly Report1
29.04.GeneDx Holdings Corp.: GeneDx Reports First Quarter 2024 Financial Results and Business Highlights116Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from...
► Artikel lesen
23.04.GeneDx Holdings Corp.: GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset112STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo...
► Artikel lesen
04.04.GeneDx Holdings Corp.: GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 20242
14.03.GeneDx Holdings Corp.: GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics1
26.02.GeneDx Holdings Corp.: GeneDx to Participate in 44th Annual Cowen Health Care Conference1
23.02.GeneDx Holdings Corp. - 10-K, Annual Report-
21.02.Earnings call: GeneDx posts revenue rise, eyes profitability by 20251
20.02.GeneDx reports Q4 results1
20.02.GeneDx Holdings Corp.: GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024258Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins2...
► Artikel lesen
20.02.GeneDx Holdings Corp. - 8-K, Current Report-
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1